Famprofazone
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Famprofazone
- DrugBank Accession Number
- DB16702
- Background
Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin’ which is marketed in Taiwan.2 It is important to note that the drug is metabolized to methamphetamine and amphetamine in the body and can lead to positive tests results for illicit drug use.1,2 Famprofazone is included in the list of prohibited substances specified by the ‘World Anti-Doping Agency’ (WADA).3
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 377.532
Monoisotopic: 377.24671263 - Chemical Formula
- C24H31N3O
- Synonyms
- Famprofazone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- HN0NCX453C
- CAS number
- 22881-35-2
- InChI Key
- GNUXVOXXWGNPIV-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H31N3O/c1-18(2)23-22(17-25(4)19(3)16-20-12-8-6-9-13-20)26(5)27(24(23)28)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3
- IUPAC Name
- 1-methyl-5-{[methyl(1-phenylpropan-2-yl)amino]methyl}-2-phenyl-4-(propan-2-yl)-2,3-dihydro-1H-pyrazol-3-one
- SMILES
- CC(C)C1=C(CN(C)C(C)CC2=CC=CC=C2)N(C)N(C1=O)C1=CC=CC=C1
References
- General References
- Chan KH, Hsu MC, Tseng CY, Chu WL: Famprofazone use can be misinterpreted as methamphetamine abuse. J Anal Toxicol. 2010 Jul-Aug;34(6):347-53. doi: 10.1093/jat/34.6.347. [Article]
- National Center for Advancing Translational Sciences - Famprofazone [Link]
- World Anti-Doping Agency: Prohibited In-Competition [Link]
- External Links
- Human Metabolome Database
- HMDB0041891
- ChemSpider
- 3209
- ChEBI
- 93799
- ChEMBL
- CHEMBL1475693
- Wikipedia
- Famprofazone
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0602 mg/mL ALOGPS logP 3.52 ALOGPS logP 4.44 Chemaxon logS -3.8 ALOGPS pKa (Strongest Basic) 9.1 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 26.79 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 116.98 m3·mol-1 Chemaxon Polarizability 43.79 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0029000000-c5ac109a2ed37aca1a85 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0019000000-daa37602e4722ca4012a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004l-2191000000-74a26e4fe7f60489e250 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0290000000-c1f18096dd06b621af2a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0931000000-6ba06fbd14f9c67674d4 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00g0-1951000000-bb7d5359a147969cb4d7 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 200.6985731 predictedDarkChem Lite v0.1.0 [M-H]- 196.35971 predictedDeepCCS 1.0 (2019) [M+H]+ 200.7622731 predictedDarkChem Lite v0.1.0 [M+H]+ 198.7177 predictedDeepCCS 1.0 (2019) [M+Na]+ 200.8448731 predictedDarkChem Lite v0.1.0 [M+Na]+ 205.76028 predictedDeepCCS 1.0 (2019)
Drug created at July 07, 2021 15:27 / Updated at July 12, 2021 03:34